---
title: "Shuttle Pharmaceuticals Holdings, Inc. Q2 2026: Revenue $0 Net loss $(3.15M), EPS $(3.10) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300056959.md"
description: "Shuttle Pharmaceuticals Holdings reported Q2 2026 results with $0 revenue and a net loss of $(3.15M), improving from the prior year's $(3.71M). The company is pivoting from clinical development to AI and digital infrastructure, having acquired Molecule.ai assets and merged with United Dogecoin. Resources are being reallocated to support mining rigs, co-location activities, and AI platform development following capital raised through public offerings."
datetime: "2026-09-24T16:11:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300056959.md)
  - [en](https://longbridge.com/en/news/300056959.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300056959.md)
generator: "portal-rs"
---

# Shuttle Pharmaceuticals Holdings, Inc. Q2 2026: Revenue $0 Net loss $(3.15M), EPS $(3.10) — 10-Q Summary

Shuttle Pharmaceuticals Holdings, Inc. reported second-quarter 2026 results reflecting a continuing transition of the business, with revenue of $0 and a net loss of $(3.15M), or diluted loss per share of $(3.10), compared with a net loss of $(3.71M) and diluted loss per share of $(32.91) in the year-ago quarter.

**Financial Highlights**

-   Revenue: $0 for Q2 2026, unchanged from $0 in the year-ago quarter.
-   Net income: Net loss of $(3.15M) for Q2 2026, improved from a net loss of $(3.71M) in the year-ago quarter.
-   Diluted earnings per share: $(3.10) for Q2 2026, versus $(32.91) in the year-ago quarter.

**Business Highlights**

-   Acquisition of Molecule.ai assets to integrate an AI-driven molecular discovery platform and accelerate early-stage drug R&D.
-   Completed merger with United Dogecoin, making it a subsidiary focused on building energy-first digital infrastructure for mining, AI and HPC workloads.
-   Strategic pivot from clinical development to AI and digital infrastructure: wound down Ropidoxuridine trials and reallocated resources toward AI and infrastructure initiatives.
-   Raised capital through a public offering and PIPE to fund marketing, AI development, and expansion of digital infrastructure via United Dogecoin.
-   Initial investments in technology deployment: purchased mining rigs, initiated co-location activities, and began development and amortization of the Molecule.ai platform.

Original SEC Filing: Shuttle Pharmaceuticals Holdings, Inc. \[ SHPH \] - 10-Q - Sep. 24, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [SHPH.US](https://longbridge.com/en/quote/SHPH.US.md)
- [TDOG.US](https://longbridge.com/en/quote/TDOG.US.md)
- [GDOG.US](https://longbridge.com/en/quote/GDOG.US.md)
- [BWOW.US](https://longbridge.com/en/quote/BWOW.US.md)
- [TXXD.US](https://longbridge.com/en/quote/TXXD.US.md)

## Related News & Research

- [House of Doge Partners With Newly Formed Dogecoin Labs to Accelerate Dogecoin Ecosystem Growth | HODO Stock News](https://longbridge.com/en/news/302558833.md)
- [Shuttle Pharmaceuticals corrects pre-funded warrants issued to 9,741,751 shares as of Sept. 9](https://longbridge.com/en/news/300055467.md)
- [Dogecoin Labs Launches to Expand DOGE Payments, DeFi, Real-World Adoption](https://longbridge.com/en/news/302560755.md)
- [Zone Frontier Completes Pivot to AI Infrastructure Focus](https://longbridge.com/en/news/301894638.md)
- [Elon Musk issues warning to Democrats considering Tesla, SpaceX investigations](https://longbridge.com/en/news/302622152.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**